项目负责人伊万·马丁教授表示："尽管小鼠模型为骨髓研究奠定了基础，但人类与动物的生物学差异显 著。新模型能更精准地模拟人体造血机制，尤其在疾病建模和药物筛选中具有不可替代的优势。" 团队成员安德烈斯·加西亚博士补充道，该系统有望减少血癌研究中对动物试验的依赖，符合科研伦理 中"替代、减少、完善"的原则。不过，当前模型尺寸较大，若用于高通量药物测试，需进一步微型化以 适应多化合物并行实验的需求。 这项研究不仅为血液疾病机制探索提供了新工具，更标志着人类在体外模拟复杂器官功能领域迈出了关 键一步。未来，该技术或可拓展至个性化医疗领域。通过提取患者自身细胞构建专属骨髓模型，医生能 提前测试不同疗法的效果，为血癌患者定制最优治疗方案。团队强调，这一应用目前仍需克服技术瓶 颈，距离临床落地尚需时日。（记者张梦然） 瑞士巴塞尔大学研究团队在最新一期《细胞·干细胞》上发表了一项突破性成果：他们首次在实验室中 用人类细胞构建出高度仿真的三维骨髓组织模型。该模型完整复现了骨髓中血管、骨细胞、神经及免疫 细胞等复杂结构，为血癌研究、药物测试及替代动物试验提供了全新平台。 骨髓作为人体"血液工厂"，其内部由多种细胞构成的微环境对血 ...

骨髓作为人体"血液工厂"，其内部由多种细胞构成的微环境对血液生成至关重要，尤其在骨表附近的内 质生位，不仅调控造血过程，还与血癌耐药性密切相关。然而，传统研究依赖动物模型或简化的二维细 胞培养，难以真实反映人类骨髓的复杂性。 来源：科技日报 图片来源：瑞士巴塞尔大学 科技日报北京11月19日电 （记者张梦然）瑞士巴塞尔大学研究团队在最新一期《细胞·干细胞》上发表 了一项突破性成果：他们首次在实验室中用人类细胞构建出高度仿真的三维骨髓组织模型。该模型完整 复现了骨髓中血管、骨细胞、神经及免疫细胞等复杂结构，为血癌研究、药物测试及替代动物试验提供 了全新平台。 团队成员安德烈斯·加西亚博士补充道，该系统有望减少血癌研究中对动物试验的依赖，符合科研伦理 中"替代、减少、完善"的原则。不过，当前模型尺寸较大，若用于高通量药物测试，需进一步微型化以 适应多化合物并行实验的需求。 这项研究不仅为血液疾病机制探索提供了新工具，更标志着人类在体外模拟复杂器官功能领域迈出了关 键一步。未来，该技术或可拓展至个性化医疗领域。通过提取患者自身细胞构建专属骨髓模型，医生能 提前测试不同疗法的效果，为血癌患者定制最优治疗方案。团队强调 ...

这项研究不仅为血液疾病机制探索提供了新工具，更标志着人类在体外模拟复杂器官功能领域迈出了关 键一步。未来，该技术或可拓展至个性化医疗领域。通过提取患者自身细胞构建专属骨髓模型，医生能 提前测试不同疗法的效果，为血癌患者定制最优治疗方案。团队强调，这一应用目前仍需克服技术瓶 颈，距离临床落地尚需时日。 【总编辑圈点】 这几乎堪称再生医学与转化研究领域的一座里程碑。它突破了传统动物模型种属差异与二维培养模型过 于简单的双重局限，直接推动未来的疾病研究、高通量药物筛选及个性化治疗，还可能会帮助解决生物 医药研发中的伦理困局与周期难题。尽管这一模型的长期稳定性可能仍需优化，但它已经向人们展示了 一条全新科研路径：通过工程化模拟人体器官微环境，我们正从被动观察生命现象，转向主动"编写"疾 病与治疗的体外剧本。 新模型以羟磷灰石（骨骼天然成分）为支架，结合人工诱导的多能干细胞，通过精准调控分化信号，培 育出包含多种细胞类型的三维骨髓组织。该构造直径达8毫米，厚度4毫米，可维持人类血液生成活动数 周，且细胞组成与空间结构均高度接近真实人体组织。 项目负责人伊万·马丁教授表示："尽管小鼠模型为骨髓研究奠定了基础，但人类与动物 ...

Core Viewpoint - Oriental Yanmei (Chengdu) Biotechnology Co., Ltd. has seen its IPO application expire after six months, indicating potential challenges in its market entry and financial performance [1][2]. Company Overview - Established in 2016, Oriental Yanmei focuses on the research, production, and commercialization of regenerative medical devices and specialized medical foods [2]. - The company’s product portfolio includes two main lines: regenerative medical material injectables and medical dressings and patches [2]. Financial Performance - In 2023, Oriental Yanmei reported revenues of 12.882 million yuan, with a projected increase to 14.52 million yuan in 2024, indicating modest growth [2]. - Revenue sources are heavily reliant on non-core businesses, with medical dressings and patches generating 3.616 million yuan and peripheral products like pharmaceutical intermediates and masks contributing 7.551 million yuan in 2024 [2]. Product Development - The company has 13 candidate products for regenerative medical material injectables, with two currently in the registration review stage [2]. - The core product, XH301, is a regenerative injectable that stimulates collagen regeneration but has not yet been commercialized, resulting in no revenue for 2023 and 2024 [2]. Losses and Expenditures - Oriental Yanmei reported significant losses, with a net loss attributable to shareholders of 63.501 million yuan in 2023 and an increase to 69.383 million yuan in 2024, totaling over 130 million yuan in two years [3]. - High expenses are attributed to R&D investments of 45.726 million yuan and 44.95 million yuan for 2023 and 2024, respectively, which account for over 300% of revenue [3]. - Administrative expenses surged by 113% in 2024, and sales costs increased by 23% from 114 million yuan in 2023 to 141 million yuan in 2024 [3]. Future Outlook - The company anticipates continued losses in the short term, potentially exacerbated by increased R&D spending and efforts to advance product approvals and commercial partnerships [3]. - Oriental Yanmei acknowledges the uncertainty of achieving profitability, stating that it may never become profitable or maintain profitability if it does [3]. Funding and Valuation - The company has completed three rounds of financing, with notable investors including Shenzhen Capital Group and Shenzhen High-tech Investment [4]. - The latest funding round in April raised 90 million yuan at a per-share cost of 9.76 yuan, resulting in a post-money valuation of 1.5 billion yuan [4].

Core Viewpoint - Oriental Yanmei (Chengdu) Biotechnology Co., Ltd. has submitted its Hong Kong IPO prospectus, which has now expired after six months, with Jianyin International as the sole sponsor [1]. Group 1: Company Overview - Yanmei Biotechnology was established in 2016 and focuses on the research, development, production, and commercialization of regenerative medical devices and special medical foods [2]. - The company specializes in the development, transformation, and application of regenerative medical materials, as well as the research and development of specific all-nutrition formula foods [2]. - Yanmei Biotechnology has accumulated key technologies in the research, modification, and preparation of polymer materials and regenerative biomaterials, including the development and preparation of microspheres [2]. Group 2: Product Lines - The company has the capability to transform regenerative medical material technologies into mature products that meet market demands [2]. - As a platform enterprise for regenerative medical material technology, Yanmei Biotechnology has a strong product portfolio that includes two main product lines: regenerative medical material injectables and medical dressings and patches made from regenerative medical materials [2].

Core Insights - Enze Kangtai is a leading company in the exosome field, recognized as a national-level "specialized and innovative" small giant in China, with a strong competitive advantage in various business scenarios [1][2] - The company has established a comprehensive professional team focused on exosome research, industrial transformation, and application promotion, with significant collaborations and a healthy financial outlook [2][16] - The exosome market is rapidly growing, particularly in regenerative medicine, with significant advantages over other technologies, driving its commercialization and industrialization [9][14] Company Overview - Founded by Kong Guanyi in 2017, Enze Kangtai has developed a robust foundation in exosome research, with over 3,000 square meters of GMP laboratories and more than 500 key partnerships [1][2] - The company has achieved significant milestones, including the establishment of the first postdoctoral research station and the first expert consensus in the exosome field [2][11] - Enze Kangtai's cash flow is expected to turn positive in the second half of 2024, with a projected break-even by 2025 [2] Exosome Technology and Applications - Exosomes are nano-sized vesicles that facilitate intercellular communication, containing bioactive molecules such as proteins and nucleic acids, making them crucial for targeted drug delivery and disease treatment [4][5][7] - The global exosome market is projected to exceed $10 billion by 2030, with a compound annual growth rate (CAGR) of approximately 32.7% over the next five years [9][14] - Enze Kangtai has developed three major platforms for exosome research and application, focusing on multi-omics analysis, engineering, and large-scale production [11][12] Business Segments - Enze Kangtai operates three main business segments: exosome services, exosome raw materials, and exosome therapies [14] - The exosome service segment is the foundation of the business, providing analysis services and tools for research and early drug development [14] - The exosome raw material segment is expected to grow rapidly, as Enze Kangtai is the first company in China to offer GMP-grade exosome raw materials [14] - The exosome therapy segment is in its early stages but is anticipated to have significant potential in regenerative medicine over the next 3-5 years [14] Market Trends and Future Outlook - The Asia-Pacific regenerative medicine market is expected to grow at a CAGR of 47.2% from 2023 to 2027, surpassing Europe to become the second-largest market globally [9] - Enze Kangtai is well-positioned to capitalize on the regulatory framework for exosome products, which will align them with innovative drug standards by June 2025 [9][16] - The company is supported by strategic investments from Zhongbo Juliy, which aims to enhance its business model and governance while fostering collaboration in the exosome industry [16]

Core Insights - An international research team led by the Catalonia Institute of Bioengineering has successfully combined human kidney organoids with live pig kidneys in vitro and transplanted them back into pigs, marking a significant milestone in regenerative medicine and personalized healthcare [1][2] - The study results were published in the latest issue of Nature Biomedical Engineering, paving the way for clinical trials using human stem cell-derived kidney organoids for cell therapy [1] Group 1 - Kidney organoids are three-dimensional microstructures cultivated from human stem cells, measuring only a few micrometers, capable of replicating major kidney structures and some functions, primarily used for kidney development research and drug testing [1] - Pig kidneys, structurally and functionally similar to human kidneys, provide a realistic environment for preclinical transplantation research [1] Group 2 - The study demonstrated that 24 and 48 hours post-transplant, human kidney organoids successfully integrated into pig kidney tissue, maintained viability, and did not trigger significant immune responses [2] - The transplanted kidneys functioned normally without signs of damage or toxicity, and physiological parameters could be monitored in real-time to detect any damage or rejection [2] Group 3 - The research introduced a systematic method for rapidly generating thousands of human kidney organoids in a short time without complex components, utilizing micro-aggregation and genetic engineering techniques for high-precision and controlled production [2]

Core Viewpoint - The article discusses a groundbreaking research study from Shanghai Jiao Tong University that introduces a new paradigm in regenerative medicine, allowing for direct differentiation of human adult adipose tissue into functional organoids without the need for complex cellular manipulation, thus overcoming significant clinical challenges in the field [3][4]. Group 1: Research Breakthroughs - The study presents a novel "tissue → new tissue" reprogramming paradigm that activates the endogenous differentiation potential of adult adipose tissue, enabling the generation of various functional organoids [4]. - Three major advantages of this research are highlighted: 1. Tissue-level reprogramming that preserves the ecological niche and homeostasis of multiple cell types within adipose tissue, avoiding genomic instability risks associated with cellular manipulation [7]. 2. The breakthrough of germ layer restrictions, successfully directing adipose tissue to differentiate into functional endodermal and ectodermal organoids [7]. 3. Clinical safety assurance through a process that avoids pluripotent states and cell passage, with long-term trials showing no tumorigenicity [7]. Group 2: Methodology and Findings - The research team developed an innovative technique that maintains the natural microenvironment of adipose tissue, leading to the formation of three-dimensional active microtissues with a high proportion of mesenchymal stem cells [8]. - The reaggregated microfat (RMF) particles demonstrated significant differentiation potential, successfully constructing functional human-derived bone marrow organoids that exhibited progressive ossification and superior hematopoietic support capabilities [9]. - The study also achieved the construction of pancreatic organoids with a notable percentage of functional β-like cells, significantly enhancing insulin secretion in response to glucose stimulation [10]. Group 3: Clinical Implications - The findings suggest that adipose tissue can serve as a "natural stem cell reservoir," providing a safe, economical, and scalable treatment strategy for conditions such as diabetes, blood disorders, and nerve injuries [13]. - The research team has initiated clinical translation studies for diabetes treatment, potentially leading to a new chapter in regenerative medicine where liposuction can be utilized for significant health benefits [13].

Core Insights - Researchers at Cambridge University have developed "blood-like cells" using human stem cells, which can simulate key stages of early human development, including the generation of blood stem cells [1][2] - The new human embryo-like model accurately replicates the initiation of the hematopoietic system in embryos, providing a powerful tool for drug screening, early blood and immune system development research, and modeling blood diseases [2][3] Group 1 - The three-dimensional structures created by human stem cells exhibit self-organization capabilities, forming the three primary germ layers (ectoderm, mesoderm, and endoderm) within two days of culture [1] - By day eight, beating heart cells were observed, which in real embryos develop into the heart, and by day thirteen, functional blood cells were confirmed with visible red blood spots [1][2] - The ability to produce human blood cells in the lab marks a significant step in regenerative medicine, allowing for the potential creation of genetically matched blood cells for patients, thus avoiding immune rejection [2] Group 2 - The model captures the "second wave" of hematopoiesis during human development, which includes the production of adaptive lymphocytes such as T cells, opening new avenues for studying blood development in both healthy and cancerous states [2] - This research adheres to international ethical standards and has received approval from ethics committees, ensuring compliance with regulatory frameworks [1] - The technology may eventually provide tailored blood cells or hematopoietic stem cells for patients with blood diseases like leukemia, potentially saving more lives [3]

Core Viewpoint - Shanghai aims to accelerate the cultivation of future industries and breakthrough disruptive technologies by 2027, with a goal of establishing around 20 leading enterprises in future industry ecosystems by 2030 [1][3]. Summary by Relevant Sections Future Industry Development - Shanghai will focus on developing fields such as cell and gene therapy, brain-machine interfaces, biomanufacturing, and embodied intelligence, while also accelerating the cultivation of fourth-generation semiconductors, silicon photonics, 6G, and brain-like intelligence [3][7]. - The city plans to systematically layout and build future industry clusters, with a focus on six major directions: future manufacturing, future information, future materials, future energy, future space, and future health [7]. Measures and Support - The "Several Measures" document outlines 15 initiatives across six areas to enhance future industry cultivation, including financial support for innovative products and scene construction tasks, with funding up to 30% of contract amounts and a maximum of 2 million yuan [7][9]. - Shanghai has already launched several cultivation plans in areas like brain-machine interfaces and quantum computing, establishing high-quality incubators and a future industry fund with a total scale of approximately 15 billion yuan [9][14]. Investment and Financial Ecosystem - The future industry fund aims to create a multi-source investment system led by government funding, supported by enterprises and financial institutions, with a focus on early-stage quality projects and long-term value [14][15]. - As of October 10, 2023, the future industry fund has made investment decisions on 18 strategic sub-funds, with a proposed investment amount of 2.215 billion yuan, and has focused on nine key strategic projects with an investment of 399 million yuan [15]. Cluster Development - Shanghai is planning to create national-level future industry pilot zones and has initiated the construction of several future industry clusters in areas like Pudong and Minhang, with support of up to 2 million yuan for qualifying cluster construction entities [11][12]. - The brain-machine interface future industry cluster is being developed to become a global innovation hub, focusing on clinical trials and incubation of disruptive technologies [12].